Will ADMA's FY2026 gross margin exceed 60%?

FY2025 gross margin was 57.4% with Q4 2025 hitting 63.8%. The trajectory is clear: ASCENIV mix shift (from 60% to 70% of revenue) drives margin expansion because ASCENIV sells at 5.5-6x standard IVIG pricing. FY2026 will be the first full year of Yield Enhancement, which adds extracted product from the same plasma volume — a genuine manufacturing efficiency. If ASCENIV mix reaches 75% and Yield Enhancement is fully productive, 60%+ full-year margin is achievable. The Q4 exit rate already exceeds 60%, and structural mix improvement should sustain this. The risk is plasma cost inflation or production issues with Yield Enhancement at scale.

The math is instructive. FY2025 gross margin was 57.4% = $293M gross profit on $510.2M revenue. For FY2026 at $635M revenue, 60% gross margin = $381M gross profit. This requires $88M incremental gross profit on $125M incremental revenue, implying 70%+ gross margin on incremental revenue. Since incremental revenue is heavily ASCENIV (5.5-6x priced), incremental margins should indeed be well above 60%. The concern is whether Q1-Q2 2026 margins could dip below 57% due to timing effects, pulling down the full-year average. Quarterly variation of 200-400bps is normal. Full-year average of 60% requires consistent H2 performance above 62%.

I focus on potential headwinds to margin expansion. Plasma input costs are subject to donor fee competition and could increase. Yield Enhancement at full scale is new — first-year production learning curve costs could compress margins versus the Q4 2025 peak. If revenue growth is back-end loaded (as discussed in the revenue market), H1 margins could be lower due to lower volume absorption of fixed costs. The $6.2M voluntary withdrawal charge in FY2025 was non-recurring but similar quality events could recur. Overall, I lean slightly above 50% that full-year exceeds 60%, but it is not a foregone conclusion.

The structural margin expansion story is compelling. ASCENIV at 70%+ mix with 5.5-6x pricing creates a structural margin floor. Q4 2025 at 63.8% demonstrates the achievable level. Yield Enhancement adds volume without proportional cost increase. For full-year to miss 60%, margins would need to average below 58% in Q1-Q3, which seems unlikely given the ASCENIV mix trajectory. The trend is clearly upward: 51.5% to 57.4% to 63.8% (Q4 exit). Even with some quarterly variation, full-year above 60% is the base case.

The question is really whether the Q4 2025 margin spike to 63.8% represents a new steady state or an anomalous quarter. If it is the new normal, then full-year 60%+ is virtually certain. If Q4 had one-time favorable factors, margins could settle at 58-60%. Key inputs: ASCENIV mix continuing to rise (supports margin), Yield Enhancement fully operational (supports margin), but plasma cost variability and potential production issues provide downside risk. I give more weight to the structural mix shift thesis than to quarterly noise. Lean YES.

ADMA FY2026 Adj. EBITDA guidance of >$360M on >$635M revenue implies 57%+ EBITDA margin, which would be extraordinary for a biopharmaceutical company. If EBITDA margin is 57%, gross margin must be well above 60% since EBITDA excludes SG&A and R&D. This suggests management itself expects 60%+ gross margins. Management guidance embeds an implicit gross margin assumption that exceeds our threshold. Combined with Q4 exit rate and structural mix shift, lean YES.

Q4 2025 exit rate of 63.8% already above threshold. ASCENIV mix shift is structural. Yield Enhancement adds efficiency. FY2025 was 57.4% and trajectory is upward. 60%+ full-year is achievable. Lean YES.

Margin expansion from 51.5% to 57.4% to 63.8% (Q4) is a clear trend. ASCENIV at 5.5-6x pricing is the driver. 60% full-year is between FY2025 (57.4%) and Q4 exit (63.8%), which is a reasonable midpoint expectation. Moderate-to-good probability.

EBITDA guidance implies management expects high gross margins. ASCENIV mix shift is continuing. Yield Enhancement is real manufacturing improvement. Plasma cost risk exists but is manageable. 60%+ full-year is the base case given the structural drivers.